

# NEWSLETTER

Volume 2, JUNE 2021



## ANNOUNCEMENT

- We are pleased to share that HCC Nurses group have initiated education program to enhance knowledge.
- Webinars are held on last Tuesday of every month.


## WE WELCOME ON BOARD NEW INSTITUTIONAL PARTNERS AND DATA ENTRY OPERATORS

- Asian Institute of Medical Sciences, Faridabad
- Believers Church Medical College Hospital, Thiruvalla
- N Karuna Sri placed at Department of Department of Medical Oncology, Nizam' s Institute of Medical Sciences, Punjagutta, Hyderabad
- Mayur Manohar Dingankar and Mayur Sawant placed at Adult Hematolymphoid Department, Tata Memorial Centre, Mumbai
- Supriya M placed at Department of Medical Oncology, Cancer Institute W.I.A, Adyar, Chennai
- Lovish Aggarwal placed at Department of Hematology, Christian Medical College, Ludhiana
- Jagsahib Kaur at Department of Medical Oncology, Asian Institute of Medical Science, Faridabad
- Ms. Priya P M placed at Department of Medical Oncology, Ramaiah Medical College & Hospitals (RMCH), Bengaluru

**HCC IS DEEPLY GRATEFUL TO ITS INDIVIDUAL & CORPORATE SUPPORTERS FOR THEIR GENEROSITY**

# THE FIRST PAPER PUBLISHED IN THE BRITISH JOURNAL OF HEMATOLOGY

"Outcomes in adolescent and young adult acute lymphoblastic leukaemia: a report from the Indian Acute Leukaemia Research Database (INwARD) of the Hematology Cancer Consortium (HCC)".



Flowchart depicting the outcomes of patients who were included in the registry.

- Of the 1383 patients, only 1141 started therapy (induction) and 863 (76%) achieved complete remission (CR).
- At last follow-up, 574 were in CR and on follow-up. A total of 336/1383 (24%) patients either did not start therapy (N = 242), or abandoned therapy after starting induction (N = 94).
- Comparison of induction outcomes between those treated with 'paediatric' and 'adult' protocols. There were no differences in terms of achievement of CR (76% vs. 73%, P = 0.509), induction mortality (4.7% vs. 3.2%, P = 0.842), or minimal residual disease (MRD) positivity rate (36% vs. 42%, P = 0.382).
- The commonest cause of induction mortality was infection (56%) followed by progressive disease (23%).

[HTTPS://ONLINELIBRARY.WILEY.COM/DOI/10.1111/BJH.17268](https://onlinelibrary.wiley.com/doi/10.1111/bjh.17268)

# CLINICAL TRIALS

## Trial 1

Study Title: Induction Related Mortality Score in Acute Myeloid Leukemia: Prospective Validation Study

- Duration of study: 4 years
- Date of Study commencement: 1st July, 2020
- No of Centres participating in this study : 17
- CTRI Registration No: CTRI/2020/07/026450
- Update :Out of 17 centres, 15 centres have received IRB approval. Total 573 AML cases are registered till date

## Trial 2

Study Title: Evaluation of the safety and efficacy of generic low-dose Dasatinib for frontline therapy in chronic phase chronic myeloid leukemia - A multi-center phase II single arm study

- Duration of Study: 2 years
- Date of Study commencement: October 2020
- No of Centres participating in this study: 12
- CTRI Registration No: CTRI/2020/10/028317
- Update: Out of 12 centres, 11 centres have received IRB approval. Total 53 cases are registered for the study

## COVID-19 Hematological Cancers Registry of India (CHCRI)

Study Design: Observational [Patient Registry]

Observational Model: Case-Only

Time Perspective: Prospective and Retrospect

Actual Study Start Date : 1st November, 2020

Update: 777 cases ; the study period has been extended to July 2021

# WEBINAR

DATE	TOPIC	SPEAKER
30-01-2021	COVID VACCINATION AND HEMATOLOGICAL MALIGNANCIES	PRIYA SAMPATHKUMAR, MD CONSULTANT DIVISION OF INFECTIOUS DISEASES AND CHAIR MAYO INFECTION CONTROL COMMITTEE MAYO CLINIC ROCHESTER, MINNESOTA
27-04-2021	CVAD- PICC INSERTION CARE & MAINTENANCE	MS. SHEELPA N RASKAR SR. NURSE DEPARTMENT OF CVAD TATA MEMORIAL HOSPITAL, MUMBAI
25-05-2021	ROLE OF IMMUNOTHERAPY IN CANCER TREATMENT	MRS. ABIJAH PRINCY B NURSE MANAGER HEMATO- ONCOLOGY NURSING DEPARTMENT CMC, VELLORE

**WEBINAR RECORDINGS IS AVAILABLE ON THE WEBSITE [HTTP://HEMECANCER.ORG/](http://HEMECANCER.ORG/)  
REGISTER AS A MEMBER TO ACCESS RECORDINGS – [HTTP://HEMECANCER.ORG/WEBINAR-RECORDING.PHP](http://HEMECANCER.ORG/WEBINAR-RECORDING.PHP)**